Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sativex in advanced cancer pain
NCT01262651Phase 3Completed
- Sponsor
- GW Pharmaceuticals
- Start
- Nov 2010
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial in cancer pain comparing Nabiximols with Placebo (2 arms). Primary endpoint: Percent Improvement From Baseline In Mean NRS Average Pain At End Of Treatment at Day 36. Started Nov 2010; status: completed.
02
Drugs
cannabis extract
03
Conditions
cancer pain
Beyond the preview
Go deeper on NCT01262651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01262651.